The American Diabetes Association (ADA) meeting highlighted key themes that a positive read across to AREC. The conference came swiftly post Medtronic announcing its intent to separate its diabetes business into a new standalone company. At ADA itself, the focus was on Type 2 diabetes (T2D) and new players in the continuous glucose monitoring (CGM) and automated insulin market. The ADA Standards of Care 2025 emphasised the use of insulin pumps, preferably with CGM, for managing diabetes in youths/adults on multiple daily injections with T2D. The rationale is that as the prevalence of diabetes continues to rise and technological advancements such as CGM and insulin pumps evolve, it becomes easier for patients to manage their condition. We believe that AREC is well positioned to enhance patients’ quality of life and outcomes through improved glucose control with its concentrated ultra rapid insulin (AT278).
